DLL4
Reaktivität: Human
WB, ELISA, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
You, Sandalcioglu, Dammann, Felbor, Sure, Zhu: "Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations." in: Journal of cellular and molecular medicine, Vol. 17, Issue 3, pp. 407-18, (2013) (PubMed).
Villaamil, Gallego, Valladares-Ayerbes, Caínzos, Aparicio: "Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway." in: Journal of molecular signaling, Vol. 7, Issue 1, pp. 14, (2012) (PubMed).
Thurston, Noguera-Troise, Yancopoulos: "The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth." in: Nature reviews. Cancer, Vol. 7, Issue 5, pp. 327-31, (2007) (PubMed).